• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 14, 2017

View Archived Issues

In the clinic

Biotron Ltd., of Sydney, Australia, initiated a randomized, double-blind, placebo-controlled, multicenter phase II trial (BIT225-009) with lead antiviral drug, BIT225, together with the combination antiretroviral therapy Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate, Gilead Sciences Inc.), in treatment-naïve patients with HIV-1 infection. Read More

Other news to note

Mateon Therapeutics Inc., of South San Francisco, said it was encouraged by preliminary data from four different syngeneic mouse models studying the company's lead investigational drug CA4P when combined with checkpoint inhibitors. Read More

Financings

Treos Bio Ltd., of San Francisco, said it completed an $8 million funding through a group of private investors. Read More

Aeterna Zentaris seeks second go with FDA on Macrilen

Aeterna Zentaris Inc. completed a full review of data from its confirmatory phase III trial of oral Macrilen (macimorelin) for use as a growth hormone stimulation test to assess growth hormone deficiency in adults (AGHD) and concluded the data were sufficient to make a second run at registration with the FDA. In 2014, the agency issued a complete response letter (CRL) on the new drug application. Read More

Zosano Pharma reports pivotal trial win for migraine patch Zotrip

Zosano Pharma Corp.'s migraine-targeting zolmitriptan-coated microneedle patch, M207, met both co-primary endpoints of the company's pivotal phase III Zotrip trial, delivering freedom from pain at two hours for 41.5 percent of treated patients and relieving the most bothersome symptom for a majority of those treated at the same time point. Read More

Changing the channel to address opioid epidemic while treating pain

NEW YORK – The 21st Century Cures Act signed into U.S. law last year included a provision for $500 million in funding for prevention and treatment programs targeting the opioid epidemic. Read More

Pakistan's biopharma sector struggles to establish regulations

KARACHI, Pakistan – Facing a chronic shortage of regulations, the biopharmaceutical industry in Pakistan is struggling to get traction despite widespread need and huge market potential. With a population that is rapidly approaching 200 million, Pakistan's pharmaceutical sector sees high growth potential, but it's held back by a lack of regulations that often translates into chronic shortages of essential medicines. Read More

Immuron sees 'limitless platform' in cow colostrum immunotherapies

PERTH, Australia – After announcing its plans for an IPO on Nasdaq, Aussie biotech Immuron Ltd. said it is ramping up its phase II program for its immunotherapy IMM-124E in non-alcoholic steatohepatitis (NASH). Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Stock merger illustration

    Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty

    BioWorld
    Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its adversary, Curevac NV, through an...
  • Multiple myeloma illustration

    Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset

    BioWorld
    Cullinan Therapeutics Inc. swept up ex-China rights to a multiple myeloma-targeting BCMAxCD3 bispecific T-cell engager (BiTE) velinotamig from Chongqing Genrix...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe